Geneva, March 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119196) titled 'Study on the efficacy and safety of different drugs in treating restless leg syndrome and itching in maintenance hemodialysis patients' on Feb. 24.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: The Second Hospital of Tianjin Medical University
Condition:
Restless leg syndrome and itching in maintenance hemodialysis patients
Intervention:
Gabapentin group:100mg~300mg/time, maximum not exceeding 500mg, orally administered after dialysis, 3 times a week.
Pregabalin Group:75mg~150mg/time, orally taken after dialysis, 3 times a week.
Recruitment Status: Not Recruiting
Phase: N/A ...